Biomea Fusion Inc. has announced the filing of a prospectus supplement with the U.S. Securities and Exchange Commission $(SEC.UK)$ dated June 17, 2025, relating to an underwritten offering. The offering includes 19,450,000 shares of common stock, pre-funded warrants for 550,000 shares, and accompanying warrants for up to 20,000,000 shares. The company anticipates net proceeds of approximately $37.1 million, potentially increasing to $42.7 million if underwriters fully exercise their options. The shares and warrants are issued under a shelf registration statement filed with the SEC in October 2022. The amended underwriting agreement includes standard representations, warranties, and indemnification obligations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.